Profit collapse from legacy costs; H2 recovery hopes rest on geopolitical stabilization
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade C
Prior guidance was vague (no specific FY27 targets); softer execution confirmed on Roha (25% utilization) and Consumer Products (still loss-making). Management met Q2 revenue guidance implicitly but missed on profitability due to legacy costs.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Ion Exchange faces a bifurcated story: legacy contract overruns and geopolitical headwinds crushed Q2 profits (-265.8% YoY PAT), but Industrial Products is growing strongly (+35% YoY) and a robust ₹296.9 Cr order book offers H2 recovery hopes. However, execution risk is high—Treatment Solutions needs geopolitical stabilization and order conversion, Specialty Chemicals requires successful pricing pass-through amid West Asia crisis, and Consumer Products must prove its breakeven path. Valuation likely to remain under pressure until H2 demonstrates recovery.
₹674.7 Cr
Revenue · −8.1% YoY₹-82.8 Cr
Reported PAT · −265.8% YoYCompressing
Margins · vs guidance: OverstatedDid the claims hold up?
Legacy project cost overruns fully accounted for Q2
METTreatment Solutions EBIT loss ₹121.5 Cr (vs ₹12.2 Cr loss prior year); mgmt says ~90% of negative PBT from legacy contracts
Strong order book ₹296.9 Cr will drive H2 recovery
OVERSTATEDOrder book real but treatment solutions revenue halved YoY; execution weak despite pipeline; H2 uplift requires geopolitical stabilization
Roha plant at 25% utilization, ramp-up progressing
MET25% achieved in Q2 but management acknowledged softer than expected; backward integration in final commissioning phase
Consumer Products on track for FY27 breakeven
OVERSTATEDH1 still showing ₹4.5 Cr EBIT loss despite 32% revenue growth; mgmt says marginally below expectations but projects end-FY27 breakeven
Industrial Products momentum will continue
METQ2 +35% YoY (₹136 Cr vs ₹100.9 Cr), H1 +25% YoY; strong tailwind from order inflows; EBIT at ₹86 Cr
Earnings quality
What changed since the last call
Treatment Solutions revenue collapsed
DowngradeQ2 revenue ₹149.8 Cr vs ₹295.8 Cr prior year (-49%); legacy contract cost overruns, geopolitical deferral, and revenue reversal on accounting matches all contributed.
Roha plant now operational but soft ramp
DowngradeCommissioned Sept 2025, now running at ~25% utilization (vs prior hope for faster ramp). Facility cost and West Asia input inflation weighing heavily; ~7% of specialty chem margin compression attributed here.
Industrial Products strong momentum
UpgradeQ2 +35% YoY (₹136 Cr), H1 +25% (₹241 Cr); EBIT at ₹86 Cr (vs ₹74 Cr). Order inflow of ₹81.3 Cr in Q2 driven by medium-sized and Hyundai deal. Segment expected to maintain growth.
Consumer Products still unprofitable
DowngradeH1 EBIT loss ₹4.5 Cr despite 32% revenue growth (₹212.9 Cr). Mgmt says marginally below expectations but still targeting FY27 end breakeven—appears optimistic.
Specialty Chemicals pricing pass-through in progress
NeutralRevenue +17% YoY but EBIT only ₹22.5 Cr; cost inflation from West Asia not yet fully passed through. Mgmt says domestic market seeing better acceptance, international slower.
The Q&A
Analysts probed hard on legacy cost quantum, Roha timeline, Hyundai contract specifics, and Consumer Products path to profitability. Management defended but hedged on contract-level margins, Hyundai FY27 revenue (would not quantify), and provided vague timelines on backward integration.
Specialty Chemicals margin drivers — Prathamesh Sawant, Abakkus Investment Managers
AnsweredRoha facility ~7% impact at segment level; West Asia crisis 7-8%; remainder from exchange gain. Mgmt says still in price pass-through phase, expects recovery.
Treatment Solutions cost overrun — Pratik Kothari, Unique PMS
AnsweredLegacy contracts expected cost overrun fully in Q2 numbers; been discussing for ~8 quarters; we've reached the bottom. No further material impact expected.
Roha backward integration completion — Deepak, Sundaram Mutual Fund
PartialFinal phase of commissioning ongoing. Should be completed within this financial year. Once done, will see favorable impact on profitability.
Hyundai contract FY27 revenue — Deepak, Sundaram Mutual Fund
DodgedWill not quantify specific contract revenue. Project is progressing; we expect a portion of revenue in FY27. Most execution planned for H2 per contractual terms.
Consumer Products breakeven timeline — Homiar Irani, independent investor
PartialPlan is to reach break-even by end of FY27. H1 was marginally below but our assessment is division should move towards break-even by year-end.
Government receivables and Jal Jeevan exposure — Gaurav Patel, individual investor
AnsweredJal Jeevan is less than 10% of overall receivables. Most backlog is industrial-side. Fund flow improving but calibrating dispatch in proportion to funds received.
Guidance
No specific FY27 consolidated revenue target stated
LowPrior call guidance was vague; implies conservative posture. Management focusing on segment-level execution (Treatment Solutions recovery, Industrial growth, breakeven targets).
Specialty Chemicals: expect improvement as Roha ramp-up progresses and pricing gains traction
MediumCurrently compressed 18% at segment level due to facility cost and input inflation. Mgmt expects single-digit margin recovery by end of year.
Treatment Solutions: return to 'average margin' in H2 with legacy contracts behind
MediumCurrently deeply loss-making; mgmt implies positive EBIT in H2 once order book executes and legacy overrun is past.
Consumer Products: reach breakeven by end of FY27
LowH1 still loss-making (-₹4.5 Cr EBIT) despite 32% growth. Target is aspirational given trajectory; mgmt says marginally below expectations.
CWIP balance ₹240 Cr as of Sept 2026; major investments in Roha backward integration, Ankleswar expansion, membrane UF facility Goa
HighRoha backward integration expected complete by FY27 end. Goa membrane expansion tied to Mann & Hummel partnership (commissioning targeted FY27 end).
Risks the call surfaced
Legacy contract overruns (Treatment Solutions)
HighCost overruns on legacy projects estimated at ~₹100 Cr, impacting Q2 by ~₹82.8 Cr net loss. While mgmt claims bottom reached, further adverse impacts could arise during final execution phases.
Geopolitical and macro headwinds
HighWest Asia crisis raising specialty chemical input costs (7-8% margin drag). Middle East dispatches being deferred due to geopolitical tensions, impacting Treatment Solutions H2 uplift expectations. Further escalation could delay more orders.
Roha facility ramp-up execution
HighRoha plant commissioned Sept 2025, running at ~25% utilization in Q2. Backward integration still in commissioning phase. Facility cost and input inflation both dragging margins. If ramp-up slows further, recovery timeline extends.
Execution risk on Treatment Solutions order book conversion
HighTreatment Solutions has strong order backlog of ₹296.9 Cr total (₹3,000 Cr industrial portion), but execution in first half was weak (revenue fell 49% YoY). Management expects significant H2 ramp, but geopolitical delays and contract complexity introduce execution risk.
Consumer Products profitability risk
MediumConsumer Products grew 30% YoY in Q2 but still unprofitable (-₹4.1 Cr EBIT). H1 loss ₹4.5 Cr. Mgmt's target of FY27 end breakeven is based on aspirational projections; actual execution may fall short.
Government receivables and fund flow risk
Medium~10% of receivables tied to Jal Jeevan Mission contracts. Fund flow has been slower than expected, forcing company to calibrate dispatch in proportion to funds received. Further delays could impact liquidity.
Management
Score 6/10. Transparent on headwinds (legacy costs, geopolitical risk, input inflation) but defensive on specifics (Hyundai contract FY27 revenue, Consumer Products margin path, contract-level profitability). Hedged timeline estimates. Mixed track record: Industrial Products delivering (+35% YoY), Specialty Chemicals growing (+17%) but margin-compressed, Consumer Products growing but still unprofitable. Treatment Solutions collapsed due to legacy cost misestimates, suggesting planning/estimation issues.
1 · Q3 FY27 (Oct-Dec 2026)
Treatment Solutions H2 execution ramp; Hyundai contract USD 52.83 Cr begins delivery phase
2 · Q3-Q4 FY27
Roha facility backward integration completion; volume ramp-up expected to reduce input cost drag
3 · End FY27 (Mar 2027)
Consumer Products breakeven target; membrane expansion (Mann & Hummel) plant commissioning in Goa
Valuation likely to remain under pressure until H2 demonstrates recovery.
Informational and educational content only. Not investment advice.